NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Medical Devices · USD

Beyond Air, Inc. (XAIR) Stock Analysis

Beyond Air, Inc. (XAIR) is a Medical Devices stock listed on NASDAQ and quoted in US Dollar.

XAIR

$3.53

−$0.06 (−1.67%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare XAIR with… →

XAIR Key Statistics

As of Sep 4, 2026
Trading
Open
$3.55
Previous Close
$3.59
Day's Range
3.50–3.64
52-Week Range
3.50–95.60
Volume
47.40K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.13
Valuation
Market Cap
$3.47M
P/E Ratio
0.01
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
0.45
EPS (ttm)Profit attributable to each share over the last twelve months.
313.20
Financials (FY)
Revenue (FY)
$7.68M+107.26%
Net Income (FY)
−$33.25M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
984.41K
1-Year Return
−91.87%
Dividend and dates
Earnings Date
November 10, 2026estimated
Avg Volume
203.09K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

XAIR Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−75.69%
2025−89.89%
2024−81.68%
2023−69.80%
2022−31.25%
2021+79.13%
2020+0.76%
2019+12.47%
2018 (partial year)+57.63%

As of September 4, 2026.

XAIR Revenue and Earnings by Fiscal Year

FY ends March
Fiscal yearRevenueNet incomeNet margin
2025$7.68M−$33.25M−433.0%
2024$3.71M−$46.63M−1258.4%
2023$1.16M−$60.24M−5197.8%
2022$0.00−$55.82M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$7.68M$252.00K−$29.04M−$33.25M−433.0%
2024$3.71M−$1.66M−$44.54M−$46.63M−1258.4%
2023$1.16M−$1.31M−$63.01M−$60.24M−5197.8%
2022$0.00−$555.00K−$52.06M−$55.82M—

Annual figures as reported, in the company's reporting currency. As of March 31, 2026.

XAIR Valuation vs Medical Devices Median

Median of 151 stocks
MetricXAIRMedical Devices medianvs median
P/E0.0126.800.0x the median
P/S ratio0.452.980.2x the median
Profit margin0.00%−1.69%1.7 pts above

Medians across 151 Medical Devices stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 7 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Beyond Air, Inc. (XAIR) carries a market capitalisation of $3.47M. It is classified in the Medical Devices industry, within the Healthcare sector. Headcount on file is 54.

XAIR last closed at $3.53 on September 4, 2026. That is −$0.06 (−1.67%) against the previous close. Over the past 52 weeks the price has ranged from $3.50 to $95.60. The latest close sits 0.86% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $7.68M. Against the prior fiscal year total of $3.71M, that is a change of +107.26%. The same year closed with a net loss of $33.25M. The reported profit margin is 0%. That is 1.7 percentage points above the Medical Devices median of −1.69%. Trailing earnings per share are 313.2.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $7.68M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The trailing P/E ratio stands at 0.01. That is 0 times the Medical Devices median of 26.8. Measured against sales, the shares trade at 0.45 times revenue. On price-to-sales that is 0.2 times the Medical Devices median of 2.98. The medians here are taken across 151 Medical Devices companies that report the metric.

Over the trailing twelve months the price has returned −91.87%. Measured over 5 years, that is −75.68% a year compounded. The reported beta is 0.13. Daily returns over the trailing 8 years annualize to a volatility of 108.92%.

Growth & Income

The record shows no dividend for XAIR.

The strongest complete calendar year on file is 2021 at +79.13%; the weakest is 2025 at −89.89%. Of the 7 complete calendar years on file, 3 finished higher. So far in 2026 the price is −75.69%.

Peer Comparison

Beyond Air, Inc. (XAIR) operates in the Medical Devices industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Beyond Air, Inc. XAIR $3.47M 0.0
Abbott Laboratories ABT $187.45B 35.1
Medtronic plc. MDT $120.46B 22.9
Stryker Corporation SYK $116.27B 31.9

The Medical Devices industry average P/E ratio is 26.8x. Beyond Air, Inc. trades at a P/E of 0.0.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Medical Devices Stocks

ABT

Abbott Laboratories

$187.45B

 MDT

Medtronic plc.

$120.46B

 SYK

Stryker Corporation

$116.27B

 BSX

Boston Scientific Corporation

$69.27B

 EW

Edwards Lifesciences Corporation

$51.82B

 DXCM

DexCom, Inc.

$33.17B
View all Medical Devices stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Beyond Air, Inc.

Beyond Air, Inc. operates as a commercial-stage medical device and biopharmaceutical company. It operates through Beyond Air, Beyond Cancer, and NeuroNos segments. The company offers Lungfit PH for the treatment of persistent pulmonary hypertension of the newborn. It is also developing LungFit PRO to treat viral lung infections, such as viral community-acquired pneumonia, including COVID-19 and bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria (NTM). In addition, the company develops ultra-high concentration NO (UNO) that is in Phase 1 clinical trial to treat solid tumors; and selective neuronal nitric oxide synthase (nNOS) inhibitor for the treatment of neurological conditions. It has a collaboration with the Yissum Research Development Company of the Hebrew University of Jerusalem, LTD to acquire the commercial rights for neuronal nitric oxide synthase inhibitors to treat autism spectrum disorder and other neurological conditions. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. was founded in 2011 and is headquartered in Garden City, New York.

Visit website →